Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Virtual Clinical Trials Market Research Report Information By Study Type (India Intraocular Lens Market), By Phase (Phase 1, Phase 2, Phase 3, and Phase 4), By Indication (Oncology, Cardiovascular, Immunology, Gastrointestinal, Respiratory, Endocrinology, Ophthalmology, and Others) and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2030.


ID: MRFR/HC/9250-HCR | 120 Pages | Author: Kinjoll Dey| April 2024

Virtual Clinical Trials Market Segmentation


Virtual Clinical Trials Study Type Outlook (USD Billion, 2018-2030)




  • Interventional




  • Observational




  • Others




Virtual Clinical Trials Phase Outlook (USD Billion, 2018-2030)




  • Phase 1




  • Phase 2




  • Phase 3




  • Phase 4




Virtual Clinical Trials Indication Outlook (USD Billion, 2018-2030)




  • Oncology




  • Cardiovascular




  • Immunology




  • Gastrointestinal




  • Respiratory




  • Endocrinology




  • Ophthalmology




  • Others




Virtual Clinical Trials Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)




    • North America Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • North America Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • North America Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others



    • US Outlook (USD Billion, 2018-2030)

    • US Virtual Clinical Trials by Study Type










      • Interventional




      • Observational




      • Others






    • US Virtual Clinical Trials by Phase




      • Phase 1




      • Phase 2




      • Phase 3




      • Phase 4






    • US Virtual Clinical Trials by Indication




      • Oncology




      • Cardiovascular




      • Immunology




      • Gastrointestinal




      • Respiratory




      • Endocrinology




      • Ophthalmology




      • Others






    • Canada Outlook (USD Billion, 2018-2030)




    • Canada Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Canada Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Canada Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others








  • Europe Outlook (USD Billion, 2018-2030)




    • Europe Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Europe Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Europe Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others




    • Germany Outlook (USD Billion, 2018-2030)


    • Germany Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Germany Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Germany Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others










    • France Outlook (USD Billion, 2018-2030)




    • France Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • France Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • France Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others



    • UK Outlook (USD Billion, 2018-2030)


    • UK Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • UK Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • UK Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others



    • Italy Outlook (USD Billion, 2018-2030)


    • Italy Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Italy Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Italy Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others



    • Spain Outlook (USD Billion, 2018-2030)


    • Spain Virtual Clinical Trials by Study Type

      • Interventional

      • Observational











      • Others




    • Spain Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Spain Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal














        • Respiratory





      • Endocrinology

      • Ophthalmology

      • Others



    • Rest Of Europe Outlook (USD Billion, 2018-2030)


    • Rest Of Europe Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • REST OF Europe Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • REST OF Europe Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others






  • Asia-Pacific Outlook (USD Billion, 2018-2030)


    • Asia-Pacific Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Asia-Pacific Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Asia-Pacific Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others










    • China Outlook (USD Billion, 2018-2030)




    • China Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • China Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • China Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others










    • Japan Outlook (USD Billion, 2018-2030)




    • Japan Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Japan Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Japan Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others




    • India Outlook (USD Billion, 2018-2030)


    • India Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • India Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • India Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others




    • Australia Outlook (USD Billion, 2018-2030)


    • Australia Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Australia Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Australia Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others










    • South Korea Outlook (USD Billion, 2018-2030)




    • South Korea Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • South Korea Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • South Korea Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others




    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)


    • Rest of Asia-Pacific Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Rest of Asia-Pacific Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Rest of Asia-Pacific Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others








  • Rest of the World Outlook (USD Billion, 2018-2030)




    • Rest of the World Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Rest of the World Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Rest of the World Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others




    • Middle East Outlook (USD Billion, 2018-2030)


    • Middle East Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Middle East Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Middle East Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others




    • Africa Outlook (USD Billion, 2018-2030)


    • Africa Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Africa Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Africa Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others




    • Latin America Outlook (USD Billion, 2018-2030)


    • Latin America Virtual Clinical Trials by Study Type

      • Interventional

      • Observational

      • Others




    • Latin America Virtual Clinical Trials by Phase

      • Phase 1

      • Phase 2

      • Phase 3

      • Phase 4




    • Latin America Virtual Clinical Trials by Indication

      • Oncology

      • Cardiovascular

      • Immunology

      • Gastrointestinal

      • Respiratory

      • Endocrinology

      • Ophthalmology

      • Others





Research Methodology on the Virtual Clinical Trials Market


Introduction


In recent years, the healthcare industry has witnessed significant changes due to advances in technology, leading to the introduction of virtual clinical trials. Virtual clinical trials are electronic versions of clinical trials which allow data collection and patient follow-up by remote means. This new methodology results in a faster research process, reduced costs and timeline, improved patient compliance, better accuracy of data, and similar outcomes to traditional on-site trials. An in-depth and detailed understanding of the industry provides valuable information to both marketers and prospective investors.


In this research report, Market Research Future (MRFR) has endeavoured to provide an insightful take on the global virtual clinical trials market and its various related aspects. The research report is multi-faceted and considers market trends, in-depth market analysis and forecasts until 2030. The key players, along with their market share, strategies, and regional growth analysis, have also been studied in detail in the report.


Research Methodology


The research methodologies adopted for this research are primary and secondary research, wherein both qualitative and quantitative data were gathered from the entire chain of the virtual clinical trials market to determine the current market scenario, future trends, growth opportunities and limitations.


In the primary research methodology, in-depth expert interviews are conducted, with healthcare experts and other participants at medical facilities such as hospitals and clinical trial centres. During the interviews, information was gathered along with opinions, views and suggestions. In the secondary research, market research reports, accumulated data sets through financial reports, industry magazines and white papers, focus group discussions and other databases were considered.


The secondary source includes Factiva, one source, Bloomberg, Hoovers, Manta and other databases from the private sector and the public sector, CMOS, CBIP, and statistical data from RTIS.


To address the report in a systematic approach, PESTLE tools and Porter’s Five Forces analysis framework were adopted. These tools provide an in-depth analysis of the emerging trends and lucrative opportunities in the market.


Market Segmentation


The virtual clinical trials market is segmented based on product type, end-user, and region.


By product type, the global virtual clinical trials market is segmented into clinical trial software systems, patient engagement systems, and data management systems.


By end user, the global virtual clinical trials market is segmented into pharmaceutical companies, contract research organizations, and research and academic institutes.


By region, the global virtual clinical trials market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.


Market Players


Notable players in the global virtual clinical trials market include Medidata Solutions, Inc. (U.S.), Parexel International Corporation (U.S.), ArunA Biomedical (U.S.), Oracle Corporation (U.S.), Webmedx Inc. (U.S.), ERT Clinical (U.S.), DATATRAK International (U.S.), eClinical Solutions (U.S.), OmniComm Systems, Inc. (U.S.), and Biotrial S.A.S. (France).


Data Collection


To understand and analyze the market, the data collection phase is done. Primary and secondary data is collected by data collection tools such as structured questionnaires, surveys, interviews and focus group discussions. Maynard, Anderson and BCG portfolio analysis techniques are used to identify the categories of virtual clinical trial products and services.


A structured questionnaire survey is conducted with key players and stakeholders in the virtual clinical trials market to collect primary data. For the secondary research, content analysis of various virtual clinical trial market reports was done.


Data Analysis


Data analysis is done to track market trends and performance. This includes the analysis of macro and microeconomic factors, market drivers and restraints, trends and opportunities, and the competitive landscape. The market dynamics analysis is done based on industry trends, drivers and opportunities. Porter’s Five Forces analysis tool is used to understand the industry dynamics and competition among the existing players.


The market size and forecast are conducted by using the top-down and bottom-up approaches. This involves deriving the estimated data from micro and macro factors and further used to validate the market size from primary sources.


Finally, the data is triangulated using data triangulation techniques to get a more accurate and reliable estimate of the market size.


Conclusion


This report is a comprehensive analysis of the global virtual clinical trials market and provides an in-depth understanding of the various factors driving the growth of the industry. The report also contains a detailed analysis of the competitive landscape, key players and their strategies, market segmentation, market dynamics, and forecast until 2030. The report will be valuable to market-oriented investors and stakeholders already in the industry.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on R&D

5.3.3. Regional Impact

5.3.4. Impact on Market Growth

6. GLOBAL VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE

6.1. Overview

6.2. Interventional

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3. Observational

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7. GLOBAL VIRTUAL CLINICAL TRIALS MARKET, BY PHASE

7.1. Overview

7.2. Phase 1

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.3. Phase 2

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.4. Phase 3

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.5. Phase 4

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8. GLOBAL VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION

8.1. Overview

8.2. Oncology

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.3. Cardiovascular

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.4. Immunology

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.5. Gastrointestinal

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.6. Respiratory

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.7. Endocrinology

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.8. Ophthalmology

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.9. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9. GLOBAL VIRTUAL CLINICAL TRIALS MARKET, BY REGION

9.1. Overview

9.2. North America

9.2.1. US

9.2.2. Canada

9.3. Europe

9.3.1. Germany

9.3.2. France

9.3.3. Italy

9.3.4. Spain

9.3.5. UK

9.3.6. Rest of Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Rest of the World

9.5.1. Middle East

9.5.2. Africa

9.5.3. Latin America

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Virtual Clinical Trials Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Virtual Clinical Trials Market

10.7. Key developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger & Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2020

10.8.2. Major Players R&D Expenditure, 2020

11. COMPANY PROFILES

11.1. Oracle Corporation

11.1.1. Company Overview

11.1.2. Products Offered

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. IQVIA Holdings, Inc.

11.2.1. Company Overview

11.2.2. Products Offered

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Dassault Systemes SE

11.3.1. Company Overview

11.3.2. Products Offered

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Medpace Holdings, Inc.

11.4.1. Company Overview

11.4.2. Products Offered

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Icon plc

11.5.1. Company Overview

11.5.2. Products Offered

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Laboratory Corporation of America Holdings

11.6.1. Company Overview

11.6.2. Products Offered

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Parexel International Corporation

11.7.1. Company Overview

11.7.2. Products Offered

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Medable, Inc.

11.8.1. Company Overview

11.8.2. Products Offered

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Clinical Ink, Inc.

11.9.1. Company Overview

11.9.2. Products Offered

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Wuxi AppTech

11.10.1. Company Overview

11.10.2. Products Offered

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Syneos Health

11.11.1. Company Overview

11.11.2. Products Offered

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL VIRTUAL CLINICAL TRIALS MARKET SYNOPSIS, 2018–2027

TABLE 2 GLOBAL VIRTUAL CLINICAL TRIALS MARKET ESTIMATES & FORECAST, 2018–2027 (USD MILLION)

TABLE 3 GLOBAL VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 5 GLOBAL VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 6 GLOBAL VIRTUAL CLINICAL TRIALS MARKET, BY REGION, 2018–2027 (USD MILLION)

TABLE 7 NORTH AMERICA: VIRTUAL CLINICAL TRIALS MARKET, BY REGION, 2018–2027 (USD MILLION)

TABLE 8 NORTH AMERICA: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 9 NORTH AMERICA: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 10 NORTH AMERICA: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 11 US: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 12 US: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 13 US: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 14 CANADA: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 15 CANADA: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 16 CANADA: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 17 EUROPE: VIRTUAL CLINICAL TRIALS MARKET, BY REGION, 2018–2027 (USD MILLION)

TABLE 18 EUROPE: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 19 EUROPE: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 20 EUROPE: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 21 GERMANY: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 22 GERMANY: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 23 GERMANY: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 24 UK: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 25 UK: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 26 UK: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 27 FRANCE: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 28 FRANCE: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 29 FRANCE: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 30 ITALY: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 31 ITALY: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 32 ITALY: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 33 SPAIN: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 34 SPAIN: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 35 SPAIN: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 36 REST OF EUROPE: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 37 REST OF EUROPE: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 38 REST OF EUROPE: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 39 ASIA-PACIFIC: VIRTUAL CLINICAL TRIALS MARKET, BY REGION, 2018–2027 (USD MILLION)

TABLE 40 ASIA-PACIFIC: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 41 ASIA-PACIFIC: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 42 ASIA-PACIFIC: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 43 INDIA: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 44 INDIA: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 45 INDIA: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 46 CHINA: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 47 CHINA: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 48 CHINA: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 49 JAPAN: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 50 JAPAN: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 51 JAPAN: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 52 SOUTH KOREA: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 53 SOUTH KOREA: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 54 SOUTH KOREA: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 55 AUSTRALIA: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 56 AUSTRALIA: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 57 AUSTRALIA: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 58 REST OF ASIA-PACIFIC: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 59 REST OF ASIA-PACIFIC: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 60 REST OF ASIA-PACIFIC: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 61 REST OF THE WORLD: VIRTUAL CLINICAL TRIALS MARKET, BY REGION, 2018–2027 (USD MILLION)

TABLE 62 REST OF THE WORLD: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 63 REST OF THE WORLD: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 64 REST OF THE WORLD: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 65 MIDDLE EAST: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 66 MIDDLE EAST: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 67 MIDDLE EAST: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 68 AFRICA: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 69 AFRICA: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 70 AFRICA: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

TABLE 71 LATIN AMERICA: VIRTUAL CLINICAL TRIALS MARKET, BY STUDY TYPE, 2018–2027 (USD MILLION)

TABLE 72 LATIN AMERICA: VIRTUAL CLINICAL TRIALS MARKET, BY PHASE, 2018–2027 (USD MILLION)

TABLE 73 LATIN AMERICA: VIRTUAL CLINICAL TRIALS MARKET, BY INDICATION, 2018–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VIRTUAL CLINICAL TRIALS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VIRTUAL CLINICAL TRIALS MARKET

FIGURE 4 GLOBAL VIRTUAL CLINICAL TRIALS MARKET SHARE, BY STUDY TYPE, 2020 (%)

FIGURE 5 GLOBAL VIRTUAL CLINICAL TRIALS MARKET SHARE, BY PHASE, 2020 (%)

FIGURE 6 GLOBAL VIRTUAL CLINICAL TRIALS MARKET SHARE, BY INDICATION, 2020 (%)

FIGURE 7 GLOBAL VIRTUAL CLINICAL TRIALS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: VIRTUAL CLINICAL TRIALS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 EUROPE: VIRTUAL CLINICAL TRIALS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 ASIA-PACIFIC: VIRTUAL CLINICAL TRIALS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 REST OF THE WORLD: VIRTUAL CLINICAL TRIALS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 12 GLOBAL VIRTUAL CLINICAL TRIALS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13 ORACLE CORPORATION: KEY FINANCIALS

FIGURE 14 ORACLE CORPORATION: SWOT ANALYSIS

FIGURE 15 IQVIA HOLDINGS, INC.: KEY FINANCIALS

FIGURE 16 IQVIA HOLDINGS, INC.: SWOT ANALYSIS

FIGURE 17 DASSAULT SYSTEMES SE: KEY FINANCIALS

FIGURE 18 DASSAULT SYSTEMES SE: SWOT ANALYSIS

FIGURE 19 MEDPACE HOLDINGS, INC.: KEY FINANCIALS

FIGURE 20 MEDPACE HOLDINGS, INC.: SWOT ANALYSIS

FIGURE 21 ICON PLC: KEY FINANCIALS

FIGURE 22 ICON PLC: SWOT ANALYSIS

FIGURE 23 LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY FINANCIALS

FIGURE 24 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS

FIGURE 25 PAREXEL INTERNATIONAL CORPORATION: KEY FINANCIALS

FIGURE 26 PAREXEL INTERNATIONAL CORPORATION: SWOT ANALYSIS

FIGURE 27 MEDABLE, INC.: KEY FINANCIALS

FIGURE 28 MEDABLE, INC.: SWOT ANALYSIS

FIGURE 29 CLINICAL INK, INC.: KEY FINANCIALS

FIGURE 30 CLINICAL INK, INC.: SWOT ANALYSIS

FIGURE 31 WUXI APPTECH: KEY FINANCIALS

FIGURE 32 WUXI APPTECH: SWOT ANALYSIS

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.